Clinical trials: Helicobacter Infections, open to volunteers
HELICOBACTER PYLORI INFECTIONS, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe
Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD).
- Trial name
- HP-MICI (NCT07292454)
- Testing
- Biopsies
- Where
- Guadeloupe
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Helicobacter Pylori Infection, Gastritis
NLR and PLR in H. Pylori-Associated Gastritis
This cross-sectional study aims to evaluate the role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as inflammatory markers in patients with Helicobacter pylori-associated gastritis at Assiut…
- Conditions
- Helicobacter Pylori Infection, Gastritis, Dyspepsia
- Trial name
- NCT07805005
- Volunteers
- 90 people
- Sponsor
- Assiut University
Helicobacter Pylori Infection
Vonoprazan-Amoxicillin Dual Therapy for Helicobacter Pylori Infection in United States Adolescents
Helicobacter pylori (H. pylori) is a common bacterial infection of the stomach that can cause chronic stomach inflammation, ulcers, and other digestive problems.
- Trial name
- NCT07860112
- Testing
- Vonoprazan, Amoxicillin
- Volunteers
- 55 people
- Sponsor
- Boston Children's Hospital
H. Pylori, SLE - Systemic Lupus Erythematosus
Associating Gastric Infection With Autoimmune Flare Severity in an Egyptians
A cross-sectional, observational study aims to evaluate the relationship between Helicobacter pylori infection and disease activity in patients diagnosed with systemic lupus erythematosus (SLE), using a combination of structured…
- Trial name
- NCT07157202
- Volunteers
- 115 people
- Sponsor
- Assiut University
Helicobacter Pylori Infection
Doxycycline for Helicobacter Pylori Rescue Treatment
Current guidelines have recommended classical bismuth-containing quadruple therapy including proton-pump inhibitor, bismuth, tetracycline, metronidazole as the empirical rescue therapy.
- Trial name
- NCT05874570
- Testing
- Esomeprazole, Bismuth Potassium Citrate, Tetracycline
- Where
- China
- Volunteers
- 368 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Gastric Cancer, Cancer Prevention
Personalised Health Recommendations to the General Population Through an Integrated AI Guided
This clinical study aims to be used to implement and validate the AIDA tool in two phases: Phase 1: Risk stratification and personalised recommendations \& Model development Phase 2: Mechanistic Model (Bioresource) development \&…
- Conditions
- Gastric Cancer, Cancer Prevention, Helicobacter Pylori Infection, Artificial Intelligence
- Trial name
- AIDA (NCT06421324)
- Testing
- Health reccommendations
- Where
- Spain
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
H.Pylori Infection
Tegoprazan- Versus PPI-based H. Pylori Eradication
In 2015, vonoprazan, a potassium-competitive blocker (P-CAB), was launched in Japan and used as an alternative for proton pump inhibitors (PPIs) for eradicating Helicobacter pylori.
- Trial name
- NCT06682533
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Soonchunhyang University Hospital
Peptic Ulcer Disease, HELICOBACTER PYLORI INFECTIONS
Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound
This observational study aims to evaluate whether combining a simple blood test (H. pylori serology) with a non-invasive abdominal ultrasound can accurately predict severe complications in patients with peptic ulcer disease…
- Conditions
- Peptic Ulcer Disease, HELICOBACTER PYLORI INFECTIONS, Helicobacter Pylori Infection, Peptic Ulcer
- Trial name
- NCT07458490
- Volunteers
- 230 people
- Sponsor
- Assiut University
Helicobacter Pylori Infection
Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication
Helicobacter pylori (H Pylori) infection is associated with functional dyspepsia, peptic ulcer disease, atrophy and gastric cancer. The bacterium has been classified as grade I carcinogen by the WHO in 1994(1).
- Trial name
- NCT06959368
- Testing
- Vonoprazan 20mg, Esomeprazole 40 mg, Amoxicillin 1 g, Clarithromycin 500 mg
- Where
- India
- Volunteers
- 484 people
- Sponsor
- Asian Institute of Gastroenterology, India
Helicobacter Infection
Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.
This study aims to compare the efficacy and safety of keverprazan-minocycline dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication, focusing on eradication rates, patient adherence, and the…
- Trial name
- NCT07904429
- Testing
- Minocycline, Keverprazan, Amoxicillin
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
HELICOBACTER PYLORI INFECTIONS, Hyperprolactinaemia
Impact of Helicobacter Pylori Infection on Prolactin Levels in Reproductive-Age Women to Determine Whether H. Pylori Infection is Associated with Elevated Prolactin Levels and Assess the Clinical Implications
The research is a cross-sectional observational study conducted at Assiut University Hospital. It will involve 75 women aged 18-45 with confirmed H. pylori infection. The study will measure serum prolactin levels and H.
- Trial name
- NCT06870773
- Volunteers
- 75 people
- Sponsor
- Assiut University
HELICOBACTER PYLORI INFECTIONS
Efficacy and Safety of 14-Day Vonoprazan-Minocycline Dual Therapy for Helicobacter Pylori Eradication
Investigators will enroll treatment-naïve H. pylori-positive patients according to the inclusion and exclusion criteria in the trial.
- Trial name
- NCT07757919
- Testing
- Vonoprazan-Amoxicillin Dual Therapy, Vonoprazan-Tetracycline Dual Therapy, Vonoprazan-Minocycline Dual Therapy
- Volunteers
- 492 people
- Sponsor
- Qilu Hospital of Shandong University
HELICOBACTER PYLORI INFECTIONS
Optimizing H. Pylori Eradication Regimen Under Intensified Acid Suppression
Background: Helicobacter pylori (H. pylori) infection affects approximately 50% of the global population and is closely associated with chronic gastritis, peptic ulcer disease, and gastric cancer. Eradication of H.
- Trial name
- NCT07750938
- Testing
- Keverprazan Hydrochloride 20 mg TID, Minocycline 100 mg (10-Day Regimen), Keverprazan Hydrochloride 20 mg BID
- Volunteers
- 316 people
- Sponsor
- Qilu Hospital of Shandong University
HELICOBACTER PYLORI INFECTIONS, Intestinal Metaplasia
Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy
The goal of this observational study is to learn how common Helicobacter pylori (H. pylori) infection is in adults without stomach or upper gastrointestinal symptoms who are having a preventive screening colonoscopy.
- Conditions
- HELICOBACTER PYLORI INFECTIONS, Intestinal Metaplasia, Barett's Esophagus
- Trial name
- G-SCOGE (NCT07346521)
- Where
- Austria
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sigmund Freud PrivatUniversitat
H. Pylori Infection
Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection
To assess the efficacy and safety of Saccharomyces boulardii combined with triple therapy containing minocycline in the initial eradication of Helicobacter pylori (H. pylori) infection
- Trial name
- NCT07012785
- Testing
- Bismuth quadruple therapy, Saccharomyces boulardii
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Zhongda Hospital
Helicobacter Pylori Infection, Dyspepsia
Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms
The objectives of this multicenter, prospective, observational study were to investigate the incidence of dyspeptic symptoms in patients with Helicobacter pylori (H.
- Trial name
- NCT06422052
- Testing
- Epidemiological questionnaire and Functional Dyspepsia Symptom Diary（FDSD）
- Where
- 26 sites in China
- Volunteers
- 2,242 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection
Tailored Vs. Empirical Helicobacter Pylori Infection Treatment
Helicobacter pylori (Hp) is a gram-negative bacterium that colonizes human gastric mucosa and is associated with chronic gastritis that can progress to severe complications such as peptic ulcer disease, gastric adenocarcinoma and…
- Trial name
- NCT06200779
- Testing
- Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test, Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®), PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
- Where
- Portugal
- Volunteers
- 160 people
- Sponsor
- Manuel Coelho da Rocha
Potassium-Competitive Acid Blocker, Proton Pump Inhibitor
Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection
This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patients with Helicobacter pylori…
- Conditions
- Potassium-Competitive Acid Blocker, Proton Pump Inhibitor, Bismuth Based Quadruple Therapy, Treatment
- Trial name
- NCT07165444
- Testing
- Potassium-Competitive Acid Blocker, Proton Pump Inhibitor
- Where
- Egypt
- Volunteers
- 320 people
- Sponsor
- Tanta University
Helicobacter Infection
Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication
This is a single-center, open-label, non-randomized, single-arm clinical study. Eligible participants who provide written informed consent will undergo screening based on inclusion/exclusion criteria.
- Trial name
- NCT07115173
- Testing
- This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.
- Volunteers
- 103 people
- Sponsor
- Samsung Medical Center
H. Pylori Infection
Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection
Background: Bismuth quadruple therapy is currently the recommended first-line regimen for Helicobacter pylori (H. pylori) infection in regions with high clarithromycin resistance.
- Trial name
- NCT04713670
- Testing
- (A) T-V14, (B) T-V7, (C) D-V14
- Where
- Taiwan
- Volunteers
- 1,200 people
- Sponsor
- National Taiwan University Hospital